

**Home Health VNA
IV Medication Clinical Fact Sheet**

IV Medication: Avycaz / Ceftazidime & Avibactam Risk Level: 1
Med Class: Antibiotics

Note: All antibiotics carry risk of hypersensitivity reaction at any time during the course of treatment
Superinfections are possible with all antibiotics

Common Uses: Gram-negative bacterial infections in:
Complicated Intra-abdominal infections in adult
and pediatric patients > 3months, complicated
urinary tract infections including Pyelonephritis
in adults and pediatric patients > 3months,
hospital-acquired bacterial pneumonia and
ventilator-associated bacterial pneumonia in
adults

Labs to Monitor: Creat Clearance

Instructions/Precautions: Recommended duration: cIAI: 5-14 days; cUTI
including pyelonephritis: 7-14 days; HABP/VABP:
7-14 days (adults only) Must be administered
over 2 hours; Dosage is affected by renal
impairment and is adjusted based on Creatinine
Clearance CrCL level – must monitor Creatinine
levels and consult with physician if levels
change. Contraindication: hypersensitivity to
components; Adverse Reactions: Most
common: Clostridium difficile associated
diarrhea, nausea, vomiting; Other: seizures and
other neurological events – especially in patients
with renal impairment, allergic reactions.

First Dose Allowed: N
Central Line Only: N
IV Push: N
Vesicant: N

Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf
See Procedure Manual: n/a

Notes: Only drugs listed as First Dose Allowed may be given in the home as a first dose and are
considered for a first dose on a case by case basis by the IV Program Manager
The IV Manager and/or Clinical Director must be consulted before a first dose referral is accepted

Risk Levels: n/a = Routinely given; Clinician must be approved to administer IV medications
1= IV Program Mgr or Clinical Director approval before referral is accepted
2= IV Program Mgr notification; Clinicians must review Special Instructions